FGFR2 is altered in 10.72% of cholangiocarcinoma patients [3].

FGFR2 is an inclusion criterion in 10 clinical trials for cholangiocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain FGFR2 status and cholangiocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 2 are phase 3 (2 open) [4].

Infigratinib and pemigatinib have evidence of efficacy in patients with FGFR2 mutation in cholangiocarcinoma [4].

FGFR2 is altered in 2.22% of malignant solid tumor patients [3].

FGFR2 is an inclusion criterion in 31 clinical trials for malignant solid tumor, of which 23 are open and 8 are closed. Of the trials that contain FGFR2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (2 open), 6 are phase 1/phase 2 (5 open), 12 are phase 2 (12 open), 1 is phase 4 (1 open), and 3 are no phase specified (3 open) [4].

FGFR2 is altered in 2.84% of urothelial carcinoma patients [3].

FGFR2 is an inclusion criterion in 11 clinical trials for urothelial carcinoma, of which 10 are open and 1 is closed. Of the trials that contain FGFR2 status and urothelial carcinoma as inclusion criteria, 2 are phase 1 (1 open), 5 are phase 1/phase 2 (5 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

FGFR2 is altered in 2.39% of breast carcinoma patients [3].

FGFR2 is an inclusion criterion in 10 clinical trials for breast carcinoma, of which 8 are open and 2 are closed. Of the trials that contain FGFR2 status and breast carcinoma as inclusion criteria, 6 are phase 1 (4 open) and 4 are phase 2 (4 open) [4].

FGFR2 is altered in 1.17% of non-small cell lung carcinoma patients [3].

FGFR2 is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 7 are open and 2 are closed. Of the trials that contain FGFR2 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 7 are phase 2 (6 open) [4].

FGFR2 is an inclusion criterion in 8 clinical trials for acute lymphoblastic leukemia, of which 7 are open and 1 is closed. Of the trials that contain FGFR2 status and acute lymphoblastic leukemia as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is altered in 3.63% of adenocarcinoma of the gastroesophageal junction patients [3].

FGFR2 is an inclusion criterion in 7 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 6 are open and 1 is closed. Of the trials that contain FGFR2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [4].

FGFR2 is altered in 4.96% of gastric carcinoma patients [3].

FGFR2 is an inclusion criterion in 6 clinical trials for gastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [4].

FGFR2 is an inclusion criterion in 5 clinical trials for B-cell acute lymphoblastic leukemia, of which 3 are open and 2 are closed. Of the trials that contain FGFR2 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open), 3 are phase 2 (1 open), and 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is altered in 16.88% of intrahepatic cholangiocarcinoma patients [3].

FGFR2 is an inclusion criterion in 4 clinical trials for intrahepatic cholangiocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain FGFR2 status and intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [4].

FGFR2 is altered in 5.0% of gastric adenocarcinoma patients [3].

FGFR2 is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (2 open) [4].

FGFR2 is altered in 2.32% of bladder carcinoma patients [3].

FGFR2 is an inclusion criterion in 4 clinical trials for bladder carcinoma, of which 3 are open and 1 is closed. Of the trials that contain FGFR2 status and bladder carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.11% of cancer patients [3].

FGFR2 is an inclusion criterion in 4 clinical trials for cancer, of which 1 is open and 3 are closed. Of the trials that contain FGFR2 status and cancer as inclusion criteria, 4 are phase 2 (1 open) [4].

FGFR2 is altered in 9.95% of endometrial carcinoma patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.73% of colorectal carcinoma patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

FGFR2 is altered in 1.39% of squamous cell lung carcinoma patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (1 open) [4].

FGFR2 is altered in 0.86% of sarcoma patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for sarcoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and sarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 0.88% of pancreatic carcinoma patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 2 are open and 1 is closed. Of the trials that contain FGFR2 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

FGFR2 is altered in 0.19% of acute myeloid leukemia patients [3].

FGFR2 is an inclusion criterion in 3 clinical trials for acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

FGFR2 is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 3 are open and 0 are closed. Of the trials that contain FGFR2 status and multiple myeloma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

FGFR2 is altered in 6.23% of melanoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for melanoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 3.39% of esophageal carcinoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR2 is altered in 1.85% of head and neck squamous cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

FGFR2 is altered in 1.56% of head and neck carcinoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.61% of glioblastoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 1.56% of non-hodgkin lymphoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR2 is altered in 1.53% of ovarian carcinoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.53% of anaplastic astrocytoma patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for anaplastic astrocytoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR2 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 0.11% of gastrointestinal stromal tumor patients [3].

FGFR2 is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and gastrointestinal stromal tumor as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR2 is an inclusion criterion in 2 clinical trials for mixed phenotype acute leukemia, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and mixed phenotype acute leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 2 clinical trials for myelodysplastic syndromes, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and myelodysplastic syndromes as inclusion criteria, 2 are phase 2 (2 open) [4].

FGFR2 is altered in 9.09% of low-grade neuroepithelial tumor, NOS patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 12.52% of endometrioid adenocarcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and endometrioid adenocarcinoma as inclusion criteria, 1 is no phase specified (0 open) [4].

FGFR2 is altered in 10.72% of bile duct carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 7.46% of malignant uterine neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 6.57% of malignant hepatobiliary neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 6.55% of hepatobiliary neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 3.89% of anaplastic oligodendroglioma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 3.03% of nasal cavity and paranasal sinus carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.84% of transitional cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FGFR2 is altered in 3.37% of ganglioglioma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 2.17% of oropharyngeal carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.17% of oropharyngeal squamous cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.48% of bladder urothelial carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR2 is altered in 2.01% of lip and oral cavity carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.01% of oral cavity carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.01% of oral cavity squamous cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for oral cavity squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and oral cavity squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.7% of cervical carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.04% of esophageal squamous cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.47% of laryngeal squamous cell carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for laryngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and laryngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.47% of malignant laryngeal neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.73% of neuronal and mixed neuronal-glial tumors patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 1.15% of low grade glioma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for low grade glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and low grade glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 1.29% of malignant salivary gland neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.6% of diffuse glioma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 1.46% of B-cell non-hodgkin lymphoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 2.4% of invasive breast carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and invasive breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

FGFR2 is altered in 1.17% of lung carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.15% of small cell lung carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR2 is altered in 1.37% of glioma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for glioma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and glioma as inclusion criteria, 1 is phase 2 (0 open) [4].

FGFR2 is altered in 1.3% of lymphoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR2 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

FGFR2 is altered in 1.42% of astrocytic tumor patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 1.08% of gallbladder carcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 1.31% of extrahepatic cholangiocarcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for extrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and extrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 0.86% of lymphocytic neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for lymphocytic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lymphocytic neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 0.88% of soft tissue sarcoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 0.9% of pancreatic adenocarcinoma patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 0.38% of histiocytic and dendritic cell neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is altered in 0.2% of myeloproliferative neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for myeloproliferative neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is altered in 0.13% of myeloid neoplasm patients [3].

FGFR2 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for B-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and B-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for hypopharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and hypopharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, B/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and mixed phenotype acute leukemia, B/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for mixed phenotype acute leukemia, T/myeloid, NOS, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and mixed phenotype acute leukemia, T/myeloid, NOS as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for non-muscle invasive bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and non-muscle invasive bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for perihilar intrahepatic cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and perihilar intrahepatic cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for T-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and T-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for T-cell lymphoblastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and T-cell lymphoblastic lymphoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].

FGFR2 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].